Washington, D.C. will no longer require people show proof of COVID-19 vaccination to enter many businesses beginning on February 15, its mayor said, joining a slew of local leaders who are dialing back pandemic restrictions as the Omicron wave ebbs.
Maryland’s life sciences ecosystem has become a key hub along the eastern shore of the United States due to its position in infectious disease research and vaccine development and manufacturing. While the state saw an infusion of billions of dollars in government financing in the development of vaccines, Maryland’s Biotechnology Investment Incentive Tax Credit, is a tool that has been used to attract venture capital funding in the state.
The U.S. Food and Drug Administration authorized the use of an additional batch of Johnson & Johnson’s one-dose Covid-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc.
The U.S. Food and Drug Administration said Johnson & Johnson must throw away millions of doses of the company’s Covid-19 vaccine that were manufactured at a problem-plagued Baltimore factory, but also cleared millions for use.
The help wanted signs are up across the biopharma industry. According to BioSpace, companies are opening and expanding facilities, which is good news for job seekers.
The U.S. Food and Drug Administration requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson Covid-19 vaccine at their facility in Baltimore.
The U.S. government will allot nearly 85 percent less Johnson & Johnson Covid-19 vaccines to states next week, data from Centers for Disease Control and Prevention (CDC) showed.
The United States put Johnson and Johnson in charge of a plant that ruined 15 million doses of the company’s Covid-19 vaccine and stopped British drugmaker AstraZeneca from using the facility, a senior health official said on April 3.
Johnson & Johnson’s manufacturing partner Emergent Biosolutions said on April 1 that the company disposed of the single batch of Covid-19 drug substance that did not meet specifications.
Johnson & Johnson said on March 31 the company had found a problem with a batch of the drug substance for its Covid-19 vaccine being produced by Emergent BioSolutions, and said the batch did not advance to the final fill-and-finish stage.
